GlassScriptPhysician profile
Amanda Primozich
NPI 1902200405
$2,262.49
in general payments reported to CMS, 2019-2025
34 companies · $390 in 2025
The $390 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $157 · 2022: $467 · 2023: $662 · 2024: $586 · 2025: $390.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,638.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,638.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $503.32 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $388.98 | 2022-2024 | Mounjaro, Zepbound, Trulicity |
| Merck Sharp & Dohme LLC | $158.32 | 2021-2024 | Verquvo, Steglatro, Belsomra |
| Exact Sciences Corporation | $155.73 | 2023-2025 | Cologuard Collection Kit |
| Abbvie INC. | $113.44 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $91.79 | 2022-2023 | |
| Amgen INC. | $85.12 | 2021-2024 | Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $69.37 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $50.25 | 2023 | Rexulti |
| Glaxosmithkline, LLC. | $48.80 | 2023-2025 | Trelegy Ellipta, Shingrix |
| Sanofi-Aventis U.S. LLC | $41.29 | 2024-2025 | |
| Amarin Pharma, INC. | $39.51 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.44 | 2021-2024 | Xifaxan |
| Nestle Healthcare Nutrition INC. | $35.76 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.63 | 2021-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $33.59 | 2024-2025 | |
| Genzyme Corporation | $32.30 | 2024 | |
| Seqirus USA INC | $32.06 | 2022-2025 | Fluad, Flucelvax |
| Janssen Pharmaceuticals, INC | $29.95 | 2022 | |
| Alexion Pharmaceuticals, INC. | $27.92 | 2024 | Ultomiris |
| Esperion Therapeutics, INC. | $27.78 | 2025 | Nexletol |
| Horizon Therapeutics Plc | $21.85 | 2023 | Krystexxa |
| Corcept Therapeutics | $21.56 | 2025 | Korlym |
| Acadia Pharmaceuticals INC | $21.44 | 2024 | Nuplazid |
| Astrazeneca Pharmaceuticals LP | $20.32 | 2023 | Fasenra |
| Genentech USA, INC. | $19.38 | 2024 | Ocrevus Zunovo |
| Philips North America LLC | $19.36 | 2023 | |
| Pacira Pharmaceuticals Incorporated | $19.08 | 2023 | Iovera, Zilretta, Exparel |
| Alk-Abello, INC | $16.92 | 2024 | Grastek, Odactra, Ragwitek |
| Astellas Pharma US INC | $16.37 | 2023 | Veozah |
| Electromed, INC. | $15.82 | 2024 | Smartvest |
| Baxter Healthcare | $15.52 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Neurelis, INC. | $12.19 | 2022 | |
| Dynasplint Systems INC. | $3.33 | 2023 | Dynasplint |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Primozich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.